Contineum Therapeutics, Inc.

NASDAQ•CTNM

CEO: Mr. Carmine N. Stengone MBA, MS

Sector: Healthcare

Industry: Biotechnology

Listing Date:

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Contact Information

10578 Science Center Drive, Suite 200, San Diego, CA, 92121, United States

858-333-5280

www.contineum-tx.com

Market Cap

$547.21M

P/E (TTM)

-7.7

17.4

Dividend Yield

52W High

$16.33

52W Low

$3.35

52W Range

90%

Rank59Top 87.6%

2.2

F-Score

Modified Piotroski Analysis

Based on 4-year fundamentals

Weak • 2.2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2022-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.49+0.00%

4-Quarter Trend

FCF

-$13.08M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Strong Cash Position Maintained Cash reserves reached $75.6M end of 2025; raised $112.7M financing net proceeds during the year.

Lead Asset Positive PET Data Reported positive top-line Phase 1b PET data for PIPE-791 in September 2025; Phase 2 IPF trial initiated December 2025.

Increased R&D Investment Total R&D expenses rose to $51.5M in 2025, driven by increased CRO costs for ongoing clinical trials.

PIPE-307 Phase 2 Data Reported Phase 2 VISTA trial for PIPE-307 (RRMS) showed acceptable safety but missed primary efficacy endpoints in November 2025.

Risk Factors

Heavy Drug Candidate Dependency Business materially harmed if lead candidates PIPE-791 or PIPE-307 fail clinical development or regulatory approval processes.

Sustained Operating Expense Increases Incurred $68.1M total operating expenses in 2025; anticipates continued increases, risking inability to sustain profitability.

Regulatory Approval Unpredictability Research, testing, and approval processes are subject to extensive, lengthy, and unpredictable regulation by FDA and foreign authorities.

J&J Discretion Over PIPE-307 Future development of PIPE-307 relies solely on J&J's discretion following completion of Phase 2 RRMS trial data.

Outlook

Anticipated Chronic Pain Data Expect top-line data from exploratory Phase 1b chronic pain trial (COAP/CLBP) for PIPE-791 in the second quarter of 2026.

Continued J&J Phase 2 Development J&J recruiting for Phase 2 MDD trial (Moonlight-1) for PIPE-307; development for RRMS remains at J&J's discretion.

Future Capital Requirements Expected Expect significant future funding needs for clinical trials, regulatory submissions, and expanding internal commercialization capabilities.

Focus on Core Pipeline Advancement Strategy centers on balanced development minimizing clinical risk for PIPE-791 (IPF/Pain) and partnered PIPE-307 (MDD/RRMS).

Peer Comparison

Revenue (TTM)

VNDA

$216.11M

+8.7%

AMRN

$183.87M

-19.6%

EDIT

$40.52M

+25.4%

Gross Margin (Latest Quarter)

AMRN

119.2%

+7.3pp

ACIU

100.0%

+0.0pp

EDIT

96.7%

+2621.3pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CAPR	$1.53B	-18.7	-71.0%	11.5%
ANNX	$721.16M	-4.3	-92.3%	11.8%
VNDA	$549.11M	-2.5	-49.2%	2.6%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 13, 2026

EPS:-$0.53

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data